Acute Respiratory Failure: Non-Invasive Ventilation, High-Flow Nasal Cannula, and Intubation Criteria

Acute respiratory failure represents the inability of the respiratory system to maintain adequate oxygenation and/or ventilation, resulting in life-threatening hypoxemia and/or hypercapnia. [KEY_CONCEPT] This condition requires immediate recognition and intervention to prevent cardiovascular collapse and organ dysfunction.

Classification by Gas Exchange Abnormality

[HIGH_YIELD] Berlin Definition of ARDS (modified from ARDS Network):

• Timing: Within 1 week of known clinical insult
• Chest imaging: Bilateral opacities not fully explained by effusions, lobar/lung collapse, or nodules
• Origin of edema: Respiratory failure not fully explained by cardiac failure or fluid overload
• Oxygenation impairment: PaO₂/FiO₂ ratio ≤300 mmHg with PEEP ≥5 cmH₂O

Severity Classifications

• Mild ARDS: PaO₂/FiO₂ 201-300 mmHg
• Moderate ARDS: PaO₂/FiO₂ 101-200 mmHg
• Severe ARDS: PaO₂/FiO₂ ≤100 mmHg

[CLINICAL_PEARL] The P/F ratio can be estimated using SpO₂/FiO₂ ratio when ABG is unavailable: S/F ratio <315 suggests P/F <300.

Clinical Signs and Symptoms

Early Signs (compensated phase):

• Dyspnea and increased work of breathing
• Tachypnea (respiratory rate >20/min)
• Tachycardia and mild hypertension
• Accessory muscle use and nasal flaring
• Altered mental status (anxiety, agitation)

Late Signs (decompensated phase):

• Cyanosis (central > peripheral)
• Diaphoresis and cool extremities
• Paradoxical breathing patterns
• Confusion progressing to obtundation
• Hemodynamic instability

[HIGH_YIELD] Critical Assessment Parameters:

Respiratory Assessment Algorithm:

1. AIRWAY ├─ Patent? → Continue assessment └─ Compromised? → Immediate intubation

2. BREATHING ├─ Rate >35 or <8/min → High-risk ├─ SpO₂ <90% despite O₂ → Escalate care └─ Accessory muscle use → Impending failure

3. CIRCULATION ├─ SBP <90 mmHg → Shock protocol ├─ HR >120 bpm → Increased metabolic demand └─ Cool extremities → Poor perfusion

4. DISABILITY (Neurologic) ├─ GCS <13 → Consider airway protection ├─ Agitation/confusion → Hypoxemia/hypercarbia └─ Somnolence → CO₂ narcosis

[CLINICAL_PEARL] ROX Index (SpO₂/FiO₂)/(Respiratory Rate) >4.88 at 12 hours predicts HFNC success and reduces need for intubation.

Physical Examination Findings

Inspection:

• Positioning (tripod, unable to lie flat)
• Skin color and diaphoresis
• Chest wall motion and symmetry

Palpation:

• Subcutaneous emphysema
• Tracheal position
• Chest expansion

Percussion:

• Dullness (consolidation, effusion)
• Hyperresonance (pneumothorax, hyperinflation)

Auscultation:

• Absent/diminished breath sounds
• Crackles (pulmonary edema)
• Wheeze (bronchospasm)
• Stridor (upper airway obstruction)

Essential Diagnostic Studies

[KEY_CONCEPT] Immediate Assessment (within 15 minutes):

Arterial Blood Gas Analysis

• pH: <7.35 (acidemia) or >7.45 (alkalemia)
• PaO₂: <60 mmHg on room air (hypoxemia)
• PaCO₂: >45 mmHg acute rise (hypercapnia)
• HCO₃⁻: Compensation assessment
• Lactate: >2 mmol/L suggests tissue hypoxia

Chest Imaging

• Chest X-ray: Initial assessment of lung pathology
• CT chest: When CXR nondiagnostic or complications suspected
• Bedside ultrasound: Rapid assessment for pneumothorax, pleural effusion

[HIGH_YIELD] Intubation Criteria Checklist:

Absolute Indications: ☐ Cardiac arrest or peri-arrest ☐ Severe shock unresponsive to resuscitation ☐ GCS ≤8 or inability to protect airway ☐ Massive hemoptysis or airway bleeding ☐ Severe acidemia (pH <7.20) with respiratory cause

Relative Indications: ☐ P/F ratio <150 despite optimal non-invasive support ☐ Respiratory rate >35/min with accessory muscle use ☐ Work of breathing causing exhaustion ☐ Hemodynamic instability exacerbated by respiratory effort ☐ Failure to improve after 1-2 hours of NIV/HFNC

Risk Stratification Tools

[CLINICAL_PEARL] Serial ROX index measurements are more predictive than single values. Declining trend suggests need for escalation to mechanical ventilation.

Laboratory Investigations

Essential Labs:

• Complete blood count (infection, anemia)
• Comprehensive metabolic panel (acid-base, electrolytes)
• Lactate (tissue perfusion)
• Troponin (cardiac involvement)
• BNP/NT-proBNP (heart failure)
• Procalcitonin (bacterial infection)

Additional Studies (based on clinical suspicion):

• Blood cultures (sepsis)
• Sputum culture and gram stain
• Legionella and pneumococcal antigens
• Influenza and respiratory virus panel
• D-dimer (pulmonary embolism)

High-Flow Nasal Cannula (HFNC)

[KEY_CONCEPT] HFNC Mechanism of Action:

• Flow rates: 30-70 L/min (adults)
• FiO₂ delivery: 21-100% precise oxygen delivery
• PEEP effect: 3-7 cmH₂O depending on flow rate and mouth closure
• Dead space washout: Reduces CO₂ rebreathing
• Heated humidification: Improves secretion clearance

HFNC Indications and Settings

Ideal Candidates:

• Type I respiratory failure with P/F ratio 150-300
• Post-extubation respiratory support
• DNI patients (do-not-intubate)
• Immunocompromised patients avoiding intubation
• Preoxygenation before procedures

Initial Settings:

• Flow rate: Start 40-50 L/min, titrate to comfort
• FiO₂: Start 40-60%, target SpO₂ 92-96%
• Temperature: 37°C (body temperature)

Non-Invasive Ventilation (NIV)

[HIGH_YIELD] BiPAP vs CPAP Comparison:

NIV Treatment Algorithm

NIV Decision Tree:

Type I Failure (P/F 100-250): ├─ CPAP 5-10 cmH₂O + FiO₂ 40-60% ├─ If no improvement in 1-2h → BiPAP └─ If worsening → Consider intubation

Type II Failure (pH 7.25-7.35, PCO₂ >45): ├─ BiPAP: IPAP 12-20, EPAP 4-8 cmH₂O ├─ Target: pH >7.30, PCO₂ decrease └─ If pH <7.25 → Consider intubation

Mixed Failure: ├─ BiPAP with high FiO₂ ├─ Aggressive monitoring └─ Low threshold for intubation

NIV Contraindications

Absolute Contraindications:

• Cardiac arrest or severe hemodynamic instability
• Upper airway obstruction
• Inability to protect airway (GCS <10)
• Severe agitation or non-cooperation
• Facial trauma preventing mask seal

Relative Contraindications:

• Recent upper GI surgery
• Active GI bleeding
• Severe claustrophobia
• Copious secretions

[CLINICAL_PEARL] NIV Failure Predictors:

• No improvement in pH or PCO₂ within 1-2 hours
• Persistent tachypnea >35/min
• Worsening mental status
• Hemodynamic deterioration
• APACHE II score >29

Monitoring and Escalation

Continuous Monitoring:

• Pulse oximetry: Target SpO₂ 92-96% (88-92% in COPD)
• Respiratory rate: Goal <25/min
• Heart rate and blood pressure
• Mental status: Alert and cooperative

Escalation Criteria:

• ROX index <4.88 at 12 hours (HFNC)
• Persistent work of breathing
• Hemodynamic instability
• Altered mental status
• Patient-ventilator asynchrony (NIV)

Pre-Intubation Preparation

[HIGH_YIELD] Rapid Sequence Intubation (RSI) Protocol:

RSI Checklist (STOP-5-LOOK):

S - SUCTION ready T - TEAM roles assigned O - OXYGEN/preoxygenation P - POSITIONING (ear-to-sternal notch)

5 - 5-MINUTE preoxygenation minimum

L - LOOK externally (Mallampati, neck mobility) O - OBTAIN IV access, monitors O - OPTIMIZE hemodynamics K - KNOW backup plan (surgical airway)

Preoxygenation Strategies

Standard Approach:

• Non-rebreather mask at 15 L/min × 3-5 minutes
• Target: EtCO₂ <5% (denitrogenation)

Advanced Techniques:

• HFNC preoxygenation: 60-70 L/min, FiO₂ 100%
• NIV preoxygenation: BiPAP with 100% FiO₂
• Apneic oxygenation: Continue HFNC during laryngoscopy

[CLINICAL_PEARL] Delayed Sequence Intubation (DSI): Sedate agitated patient first, then preoxygenate with HFNC/NIV before paralysis. Useful when cooperation needed for adequate preoxygenation.

Post-Intubation Mechanical Ventilation

Initial Ventilator Settings (ARDS Network Protocol)

Volume-Controlled Ventilation:

• Tidal volume: 4-6 mL/kg predicted body weight
• PEEP: Start 5 cmH₂O, titrate to FiO₂ (PEEP/FiO₂ table)
• Respiratory rate: 20-35/min (target pH 7.30-7.45)
• FiO₂: Start 100%, wean to target SpO₂ 88-95%
• Inspiratory time: 0.8-1.2 seconds
• Plateau pressure: <30 cmH₂O (lung-protective ventilation)

PEEP/FiO₂ Titration Strategy

Advanced Ventilation Strategies

Prone Positioning (PROSEVA Protocol)

[KEY_CONCEPT] Indications for Prone Positioning:

• Severe ARDS: P/F ratio <150 mmHg
• FiO₂ ≥0.6 and PEEP ≥5 cmH₂O
• Within 48 hours of ARDS diagnosis
• Duration: Minimum 16 hours per session

Contraindications:

• Unstable spine fractures
• Recent abdominal surgery
• Severe hemodynamic instability
• Intracranial pressure >30 mmHg

Rescue Therapies for Severe ARDS

Neuromuscular Blockade:

• Indication: P/F <120 mmHg despite optimization
• Agent: Cisatracurium 15 mg/h × 48 hours
• Monitoring: Train-of-four, depth of sedation

Extracorporeal Support:

• VV-ECMO: Severe respiratory failure, reversible cause
• Criteria: Murray score >2.5 or pH <7.20
• Timing: Early referral to ECMO center

[HIGH_YIELD] Liberation from Mechanical Ventilation:

Spontaneous Awakening Trial (SAT) + Spontaneous Breathing Trial (SBT):

Daily Assessment:

1. Hemodynamic stability (no vasopressors)
2. Adequate oxygenation (FiO₂ ≤40%, PEEP ≤8)
3. No active sedation needs
4. Mental status appropriate

SBT Parameters:

• Pressure support ≤8 cmH₂O + PEEP ≤5
• Duration: 30-120 minutes
• Success: RR <35, SpO₂ >90%, no distress

Extubation Criteria:

• Successful SBT
• Adequate cough and secretion clearance
• Patent upper airway
• Mental status appropriate

Complications of Respiratory Support

Non-Invasive Ventilation Complications

Immediate Complications:

• Gastric insufflation: Aspiration risk, decreased venous return
• Pressure sores: Nasal bridge, forehead from mask pressure
• Conjunctival irritation: Air leak around mask
• Claustrophobia: Patient intolerance, anxiety

Delayed Complications:

• Delayed intubation: Missing the window for safe intubation
• Hemodynamic compromise: Increased venous return impedance
• Patient-ventilator asynchrony: Increased work of breathing

Mechanical Ventilation Complications

[HIGH_YIELD] Ventilator-Associated Complications:

VILI Prevention Strategies (ARDS Network)

Lung-Protective Ventilation:

• Tidal volume: 4-6 mL/kg predicted body weight
• Plateau pressure: <30 cmH₂O (ideally <28 cmH₂O)
• Driving pressure: <15 cmH₂O (Pplat - PEEP)
• Permissive hypercapnia: Accept pH 7.20-7.30

[CLINICAL_PEARL] Driving pressure (Pplat - PEEP) is the strongest predictor of VILI risk. Target <15 cmH₂O by adjusting PEEP and tidal volume.

Long-Term Outcomes

Survival and Recovery

ARDS Mortality Rates:

• Mild ARDS: 20-25% mortality
• Moderate ARDS: 30-35% mortality
• Severe ARDS: 40-50% mortality

Prognostic Factors:

• Age: >65 years associated with higher mortality
• Comorbidities: Chronic organ dysfunction
• Severity scores: APACHE II, SOFA scores
• Response to treatment: P/F ratio improvement

Post-ICU Syndrome (PICS)

Cognitive Impairment:

• Incidence: 30-80% of ICU survivors
• Duration: May persist >1 year
• Risk factors: Delirium duration, sedation depth

Physical Impairment:

• ICU-acquired weakness: 25-50% incidence
• Polyneuropathy/myopathy: Prolonged paralysis
• Respiratory muscle weakness: Weaning difficulties

Psychological Effects:

• PTSD: 10-25% of ICU survivors
• Depression: 25-35% incidence
• Anxiety disorders: Variable incidence

[KEY_CONCEPT] PADIS Guidelines (Pain, Agitation, Delirium, Immobility, Sleep):

• Minimize sedation exposure
• Daily sedation interruption
• Early mobility protocols
• Delirium prevention and management
• Sleep hygiene optimization

Quality Metrics and Outcomes

ICU Performance Indicators

Process Measures:

• Time to appropriate respiratory support
• Lung-protective ventilation compliance
• Sedation protocol adherence
• Early mobility implementation

Outcome Measures:

• ICU and hospital mortality
• Ventilator-free days at 28 days
• Length of stay (ICU and hospital)
• Unplanned reintubation rates

[HIGH_YIELD] Ventilator-Free Days calculation: If patient dies within 28 days = 0 VFD. If alive and breathing unassisted = 28 minus days on ventilator. Maximum possible = 28 days.